|Bid||0.0000 x 4000|
|Ask||3.4900 x 42300|
|Day's Range||2.4600 - 2.6100|
|52 Week Range||2.2500 - 3.8900|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
INCLINE VILLAGE, Nev. , Aug. 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) Allakos Inc (NASDAQ: ALLK )(announced common stock offering) ...
Amphora NDA Resubmission Remains on Track for Q4 2019 Management to Host Conference Call Tuesday August 6, 2019 at 11:00 a.m. EDT SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: ...
INCLINE VILLAGE, Nev., July 31, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) today announced that it will release its second quarter 2019 financial results for the period ended June 30, 2019, on Wednesday, August 7, 2019, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
INCLINE VILLAGE, Nev., June 25, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) today announced the resignation of Chief Financial Officer, Peter Garcia, who will be leaving the Company effective August 15, 2019. Since joining PDL in May 2013, Mr. Garcia played an instrumental role in successfully completing the Company's convertible debt transactions, achieving an improved capital structure for the Company, and building a quality finance and accounting team. "On behalf of the Company's board of directors and the management team, I'd like to thank Pete for his leadership and many contributions during his time at PDL," said Dominique Monnet, president and CEO of PDL.
INCLINE VILLAGE, Nev., June 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) announces that at its 2019 annual meeting of stockholders held June 20, 2019, the Company's stockholders elected Natasha A. Hernday to the Company's Board of Directors. The Company also announced that its stockholders voted to re-elect Harold E. Selick, Ph.D. and Samuel R. Saks, M.D. as Directors, and approved, on an advisory basis, executive officer compensation.
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
SAN DIEGO and INCLINE VILLAGE, Nev., June 10, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc. (PDLI) (PDL) today announced the closing of the second tranche for $50 million of an aggregate $80 million strategic financing from PDL and existing Evofem investors, Invesco Asset Management, LTD. (Invesco) and Woodford Investment Management (WIM). "This investment from PDL and the support from two long-time investors enables us to execute our commercialization strategy for Amphora® and to prepare for its anticipated launch as the first-in-class Multipurpose Vaginal pH Regulator for hormone-free birth control in the second quarter of 2020, assuming FDA approval," said Saundra Pelletier, CEO of Evofem Biosciences.
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
INCLINE VILLAGE, Nev. , May 28, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive ...
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...
INCLINE VILLAGE, Nev. , May 15, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive ...
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
On a per-share basis, the Incline Village, Nevada-based company said it had profit of 5 cents. Earnings, adjusted for one-time gains and costs, were 9 cents per share. The biotechnology company posted ...
INCLINE VILLAGE, Nev. , May 9, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three months ended March 31, 2019 : ...
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.